Sumitomo Mitsui Trust Group Inc. Has $527.74 Million Stock Position in Amgen Inc. $AMGN

12 Apr 2026, 07:58 by Renee Jackson · The Cerbat Gem

Sumitomo Mitsui Trust Group Inc. lowered its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,612,368 shares of the medical research company’s stock after selling 43,704 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.30% of Amgen worth $527,744,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in AMGN. Board of the Pension Protection Fund acquired a new stake in Amgen in the fourth quarter valued at approximately $26,000. Olistico Wealth LLC acquired a new stake in Amgen in the fourth quarter valued at approximately $33,000. Cloud Capital Management LLC acquired a new stake in Amgen in the third quarter valued at approximately $34,000. Saranac Partners Ltd acquired a new stake in Amgen in the third quarter valued at approximately $37,000. Finally, Holos Integrated Wealth LLC acquired a new stake in Amgen in the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AMGN. Royal Bank Of Canada raised their target price on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Guggenheim raised their target price on shares of Amgen from $347.00 to $351.00 and gave the company a “neutral” rating in a research report on Thursday. Daiwa Securities Group raised their target price on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Argus lifted their price target on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, Jefferies Financial Group assumed coverage on shares of Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $355.84.

Check Out Our Latest Stock Analysis on AMGN

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $350.92 on Friday. The firm has a market cap of $189.39 billion, a PE ratio of 24.66, a price-to-earnings-growth ratio of 3.48 and a beta of 0.47. The firm’s fifty day moving average is $363.87 and its 200-day moving average is $335.08. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is presently 70.84%.

More Amgen News

Here are the key news stories impacting Amgen this week:

Positive Sentiment: China approval for tarlatamab expands Amgen’s lung-cancer market access and supports future revenue in a large oncology market — a meaningful commercial win for a new oncology asset. Amgen’s lung cancer drug tarlatamab wins China approval
Positive Sentiment: Phase‑4 FORWARD II gout study update: a less‑frequent Krystexxa dosing schedule could improve patient adherence and lifetime drug value, which would be positive for product uptake and revenue stability. Amgen’s FORWARD II Gout Study
Positive Sentiment: Analyst bullishness on fundamentals: Zacks argues Amgen is poised to beat earnings again, supported by its recent history of surprise results and solid guidance — this can underpin near‑term sentiment ahead of the next report. Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
Positive Sentiment: Royal Bank of Canada raised its price target to $370, signaling upside from some institutional analysts and suggesting conviction in Amgen’s mid‑term growth drivers. Royal Bank Of Canada Increases Amgen Price Target
Neutral Sentiment: Guggenheim nudged its target to $351 while retaining a neutral rating — little immediate directional impact given the price is near that level. Amgen Price Target Raised to $351 at Guggenheim
Neutral Sentiment: Short‑interest data reported for April appears inconsistent/erroneous (reads as 0 shares / NaN increase), so it’s unlikely to be a reliable driver of today’s action. (data entry)
Neutral Sentiment: Media pieces highlighting Amgen’s profitability and recent TEPEZZA subcutaneous Phase‑3 topline results reinforce the company’s longer‑term value story but are incremental to near‑term price moves. Is Amgen One of the Most Profitable Value Stocks?
Negative Sentiment: Morgan Stanley’s latest stance (equal‑weight, target raised only to $326) and other hold ratings emphasize limited near‑term upside vs. current levels — that analyst positioning is weighing on the stock. Morgan Stanley equal weight on Amgen

Amgen Company Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Five stocks we like better than Amgen